- Scholar Rock Holding Corp at JPMorgan Healthcare Conference TranscriptJan 09, 2024
- Q3 2023 Scholar Rock Holding Corp Earnings Call TranscriptNov 07, 2023$12.35 (+1.48%)Earnings
- Scholar Rock Holding Corp Overview of the Current Treatment Landscape and Unmet Needs of Patients with SMA TranscriptJul 12, 2023
- Scholar Rock Holding Corp at JPMorgan Healthcare Conference TranscriptJan 10, 2023
- Scholar Rock Holding Corp TOPAZ Phase 2 Clinical Trial Data TranscriptJun 17, 2022
- Scholar Rock Holding Corp at JPMorgan Healthcare Conference (Virtual) TranscriptJan 11, 2022
- Scholar Rock Holding Corp at Credit Suisse Healthcare Conference (Virtual) TranscriptNov 09, 2021
- Scholar Rock Holding Corp to Host KOL Discussing Apitegromab's Therapeutic Potential in Patients with SMA Call TranscriptJun 15, 2021
- Scholar Rock Holding Corp at Goldman Sachs Global Healthcare Conference (Virtual) TranscriptJun 09, 2021
- Scholar Rock Holding Corp Annual Shareholders Meeting TranscriptMay 27, 2021
- Scholar Rock Holding Corp to Announce the 12-Month Top-line Results of TOPAZ Phase 2 Trial TranscriptApr 06, 2021
- Scholar Rock Holding Corp at JPMorgan Healthcare Conference (Virtual) TranscriptJan 11, 2021
- Scholar Rock Holding Corp to Discuss the SRK-015 TOPAZ Interim Analysis Results Conference Call TranscriptOct 27, 2020
- Scholar Rock Holding Corp at Morgan Stanley Global Healthcare Conference (Virtual) TranscriptSep 16, 2020
- Q2 2020 Scholar Rock Holding Corp Earnings Call TranscriptAug 07, 2020$14.07 (+2.25%)Earnings
- Scholar Rock Holding Corp Annual Shareholders Meeting TranscriptMay 29, 2020
- Scholar Rock Holding Corp at Morgan Stanley Healthcare Conference TranscriptSep 11, 2019
- Scholar Rock Holding Corp at Oppenheimer Healthcare Conference TranscriptMar 19, 2019
- Scholar Rock Holding Corp at Cowen Health Care Conference TranscriptMar 13, 2019
- Scholar Rock Holding Corp SRK-015 Interim Phase 1 Results and Phase 2 Trial Design Conference Call TranscriptFeb 26, 2019
Scholar Rock Holding Corp TOPAZ Phase 2 Clinical Trial Data Transcript
Good day, and welcome to the Scholar Rock Conference Call. (Operator Instructions).
As a reminder, this call is being recorded. I would now like to turn the call over to [Rashmi Nofsinger], Vice President of Investor Relations and Corporate Affairs. You may begin.
Good morning, and thank you for joining us on today's call to review the 24-month extension period results from our TOPAZ Phase II clinical trial of patients with Type 2 and Type 3 spinal muscular atrophy, or SMA. The webcast slides for this call can be accessed on the Events and Presentations section of the Investor Relations page on the Scholar Rock website.
I wanted to note that we'll be making various statements about Scholar Rock's future expectations, plans and prospects that constitute forward-looking statements for the purposes of the safe harbor provisions under the Private Securities Litigation Reform Act of 1995.
Actual results may differ materially from those indicated by any forward-looking statements as a result of various
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |
![](https://static.gurufocus.com/material/money-back-guarantee.png)
![](https://static.gurufocus.com/trust_rating.png)
![](https://static.gurufocus.com/trust.png)